Harrison.ai, a Haymarket, Australia-based global healthtech company and developer of AI-powered medical diagnostic support and workflow solutions, raised US$112M in Series C funding.
The round, which brought the total amount to $240M, was led by Aware Super, ECP and existing investor Horizons Ventures. New investors, such as Australia’s National Reconstruction Fund Corporation (NRFC), Ord Minnett and Wollemi Capital Group also participated, along with existing investors including Blackbird Ventures and Alpha JWC Ventures.
The company intends to use the funds to expand its U.S. operations and grow its customer base.
Led by CEO Dr. Aengus Tran, Harrison develops radiology (Annalise.ai) and pathology (Franklin.ai) technology solutions that assist clinicians with identifying signs of cancer and other critical illnesses earlier, improving treatment decisions and patient outcomes. It uses AI to analyze CT scans, X-rays, and pathology slides, supporting clinicians in detecting and diagnosing medical conditions faster and more accurately.
The company partners with hospitals and private clinics across APAC, EMEA, the United Kingdom and United States. Further accelerating its global commercialization efforts, Harrison.ai is establishing a North American presence in Boston focusing on building its U.S. operations and growing the customer base.
Harrison.ai has already received 12 FDA clearances, and one of its CT Brain algorithms has FDA Breakthrough Device Designation and Medicare reimbursement through the New Technology Add-on Payment (NTAP).
FinSMEs
11/02/2025